FIG. 1A





KARPAS422
SUDHL4
NUDHL1
SUDHL6
CD74-L7-P1
P1
%Viability
Log [C] M

FIG. 1B


DOHH2
IgG-L7-P1
CD74-L7-P1
P1
%Viability
Log [C] M


SUDHL10
IgG-L7-P1
CD74-L7-P1
P1
%Viability
Log [C] M




SUDHL5
IgG-L7-P1
CD74-L7-P1
P1
%Viability
Log [C] M

FIG. 2 In vitro activity of CD74 ADCs and payloads in Monomac1 cell line (CTG 72h)





CD74-L7-P1
IgG-L7-P1
P1
MONO-MAC-1
KMS-20
KMS-21BM
EOL-1
NOMO-1
Kasumi-6
% Inhibition vs. Untreated
Concentration [nM]
100
50
0
-50
0.01
0.1
1
10
100
1000

FIG. 3

FIG. 4




NOMO-1
5 nM Venetoclax Combination
MONO-MAC-1
5 nM Venetoclax Combination
NOMO-1
50 nM Venetoclax Combination
EOL-1
5 nM Venetoclax Combination
MONO-MAC-1
50 nM Venetoclax Combination
% Inhibition vs. Untreated
Concentration [nM]
CD74-L5-P1
IgG1-L5-P1
P1
CD74-L5-P1 + Combination
IgG1-L5-P1 + Combination
P1 + Combination

FIG. 5


MONO-MAC-1
5 nM Compound A1 Combination
% Inhibition vs. Untreated
Concentration [nM]
NOMO-1
5 nM Compound A1 Combination
MONO-MAC-1
50 nM Compound A1 Combination
EOL-1
5 nM Compound A1 Combination
NOMO-1
50 nM Compound A1 Combination
CD74-L5-P1
IgG1-L5-P1
P1
CD74-L5-P1 + Combination
IgG1-L5-P1 + Combination
P1 + Combination



Tumor volume (mm3)
Medium+/-IgG
2400
2200
2000
1800
1600
1400
1200
1000
800
600
400
200
0
0
2
4
6
8
10
12
14
16
18
20
22
Time after randomization (days)
Untreated Control
anti-CD74_CysmAb Fc silent - 30MK
Venetoclax 50MK
IgG1-Linker-Payload Fc silent - 30MK
IgG1-Linker-Payload Fc silent 30MK
+ venetoclax 50MK
anti-CD74_CysmAb Fc silent_L5-P1 - 30MK
anti-CD74_CysmAb Fc silent_L5-P1 30MK
+ venetoclax 50MK
Antibody treatments (IV)
Venetoclax treatments (PO)

FIG. 6



% Body weight loss
Mean+/-Sem
8
6
4
2
0
-2
-4
0
5
10
15
20
25
Time after randomization (days)
Untreated Control
anti-CD74_CysmAb Fc silent - 30MK
IgG1-Linker-Payload Fc silent - 30MK
IgG1-Linker-Payload Fc silent 30MK + venetoclax 50MK
Venetoclax 50MK
anti-CD74_CysmAb Fc silent_L5-P1 - 30MK
anti-CD74_CysmAb Fc silent_L5-P1 30MK + venetoclax 50MK

FIG. 7



Untreated Control
anti-CD74_CysmAb Fc silent - 30MK
Venetoclax 50MK
IgG1-Linker-Payload Fc silent - 30MK
IgG1-Linker-Payload Fc silent 30MK + venetoclax 50MK
anti-CD74_CysmAb Fc silent_L5-P1 - 30MK
anti-CD74_CysmAb Fc silent_L5-P1 30MK + venetoclax 50MK
Antibody treatments (IV)
Venetoclax treatments (PO)
Tumor volume (mm3)
Median+/-IQR
Time after randomization (days)
2000
1800
1600
1400
1200
1000
800
600
400
200
0
0
5
10
15
20
25
30
35
40

FIG. 8



Untreated Control
anti-CD74_CysmAb Fc silent - 30MK
Venetoclax 50MK
IgG1-Linker-Payload Fc silent - 30MK
IgG1-Linker-Payload Fc silent 30MK
+ venetoclax 50MK
anti-CD74_CysmAb Fc silent_L5-P1 - 30MK
anti-CD74_CysmAb Fc silent_L5-P1 30MK
+ venetoclax 50MK
% Body weight loss
Mean+/-Sem
8
6
4
2
0
-2
-4
-6
-8
-10
-12
-14
0
5
10
15
20
25
Time after randomization (days)

FIG. 9



Untreated Control
IgG1-Linker-Payload Fc silent - 30MK
anti-CD74_CysmAb Fc silent - 30MK
Venetoclax 50MK
IgG1-Linker-Payload Fc silent 30MK + venetoclax 50MK
anti-CD74_CysmAb Fc silent_L5-P1 - 30MK
anti-CD74_CysmAb Fc silent_L5-P1 30MK + venetoclax 50MK
Antibody treatment (IV)
Venetoclax treatment (PO)
Tumor volume (mm3)
Median+/-IQR
Time after randomization (days)
2000
1800
1600
1400
1200
1000
800
600
400
200
0
0
5
10
15
20
95
100

FIG. 10



Untreated Control
anti-CD74_CysmAb Fc silent - 30MK
Venetoclax 50MK
IgG1-Linker-Payload Fc silent - 30MK
anti-CD74_CysmAb Fc silent_L5-P1 - 30MK
IgG1-Linker-Payload Fc silent 30MK + venetoclax 50MK
anti-CD74_CysmAb Fc silent_L5-P1 30MK + venetoclax 50MK
% Body weight loss
Mean+/-Sem
8
6
4
2
0
-2
-4
0
10
15
20
Time after randomization (days)

FIG. 11



Vehicle iv + vehicle po
CD74 Fc silent 30 mg/kg iv qdx1 + venetoclax
Vehicle iv + venetoclax 50 mg/kg po qd
Isotype IgG1 ADC Fc silent 30 mg/kg iv qdx1 + venetoclax
CD74-L5-P1 FC silent 30 mg/kg iv qdx1 + vehicle
CD74-L5-P1 Fc silent 10 mg/kg iv qdx1 + venetoclax
CD74-L5-P1 Fc silent 30 mg/kg iv qdx1 + venetoclax
Tumor volume [mm3] mean±SEM
0
200
400
600
800
1000
1200
0 2 4 6 8 10 12 14 16 20 30 40 50 60 70
Day post treatment initiation

FIG. 12



Vehicle iv + vehicle po
Vehicle iv + venetoclax 50 mg/kg po qd
CD74-L5-P1 Fc silent 30 mg/kg iv qdx1 + vehicle
CD74 Fc silent 30 mg/kg iv qdx1 + venetoclax 50 mg/kg po qd
Isotype IgG1 ADC Fc silent 30 g/kg iv qdx1 + venetoclax 50mg/kg po qd
CD74-L5-P1 Fc silent 30 mg/kg iv qdx1 + venetoclax 50 mg/kg po qd
CD74-L5-P1 Fc silent 10 mg/kg iv qdx1 + venetoclax 50 mg/kg po qd
Change in body weight (%T0) mean ± SEM
14
12
10
8
6
4
2
0
-2
-4
-6
-8
-10
0 2 4 6 8 10 12 14 16 20 30 40 50 60 70
Day post treatment initiation

FIG. 13



Vehicle p.o. qd + Vehicle i.v.
Venetoclax 50mg/kg p.o. qd + CD74-L34-P1 Fc Silent
Venetoclax 50mg/kg p.o. qd + CD74-L30-P1 Fc Silent
Venetoclax 50mg/kg p.o. qd + CD74-L31-P1 Fc Silent
Venetoclax 50mg/kg p.o. qd + CD74-L32-P1 Fc Silent
Venetoclax 50mg/kg p.o. qd + CD74-L33-P1 Fc Silent
Venetoclax 50mg/kg p.o. qd + CD74-L5-P1 Fc Silent
Venetoclax 50mg/kg p.o. qd + CD74-L34-P1 Fc Silent 3.3mpk
Tumor volume [mm3] mean±SEM
1400
1200
1000
800
600
400
200
0
0 1 2 3 4 5 6 7 8 9 10
Day post treatment initiation

FIG. 14



Vehicle p.o. qd + Vehicle i.v.
Venetoclax 50mg/kg p.o. qd + CD74-L34-P1 Fc Silent
Venetoclax 50mg/kg p.o. qd + CD74-L30-P1 Fc Silent
Venetoclax 50mg/kg p.o. qd + CD74-L31-P1 Fc Silent
Venetoclax 50mg/kg p.o. qd + CD74-L32-P1 Fc Silent
Venetoclax 50mg/kg p.o. qd + CD74-L33-P1 Fc Silent
Venetoclax 50mg/kg p.o. qd + CD74-L5-P1 Fc Silent
Venetoclax 50mg/kg p.o. qd + CD74-L34-P1 Fc Silent 3.3mpk
Body weight change
(% of starting weight on D0)
10
5
0
-5
-10
0 1 2 3 4 5 6 7 8 9 10
Day post treatment initiation

FIG. 15



Bacterial Transglutaminase
BTG
(10 eq.)
20% DMA, PBS
RT, overnight, 500 rpm

FIG. 16